Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vistin Pharma ASA ( (DE:VP4) ) has shared an update.
Vistin Pharma ASA plans to release its first quarter 2026 results on 24 April and will host a same-day conference call at 08:30 CET for shareholders and other interested parties. The event will include a management presentation followed by a Q&A session and will be accessible via webcast and telephone, offering stakeholders an opportunity to gain insight into the company’s recent performance and outlook.
The timing and open access format of the results presentation underline Vistin Pharma’s ongoing emphasis on transparency and engagement with the market. This communication approach may help reinforce investor confidence and maintain the company’s positioning as a focused European supplier in the Metformin segment of the pharmaceutical industry.
More about Vistin Pharma ASA
Vistin Pharma ASA is a Norwegian pharmaceutical company specializing in the production of Metformin Hydrochloride active pharmaceutical ingredient, also offered as direct compressible lubricated granules. As a solely dedicated European Metformin producer with headquarters in Oslo and a manufacturing facility in Kragerø, it supplies leading pharmaceutical companies across Europe.
Average Trading Volume: 13,966
Current Market Cap: NOK1B
See more insights into VP4 stock on TipRanks’ Stock Analysis page.